Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $823.6 million.

  • Corcept Therapeutics' Liabilities and Shareholders Equity rose 501.75% to $823.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 billion, marking a year-over-year increase of 1930.92%. This contributed to the annual value of $840.6 million for FY2024, which is 3524.22% up from last year.
  • According to the latest figures from Q3 2025, Corcept Therapeutics' Liabilities and Shareholders Equity is $823.6 million, which was up 501.75% from $801.7 million recorded in Q2 2025.
  • Corcept Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $846.5 million for Q1 2025, and its period low was $423.8 million during Q4 2021.
  • Its 5-year average for Liabilities and Shareholders Equity is $633.5 million, with a median of $594.0 million in 2023.
  • Per our database at Business Quant, Corcept Therapeutics' Liabilities and Shareholders Equity crashed by 2588.19% in 2021 and then skyrocketed by 3768.06% in 2022.
  • Over the past 5 years, Corcept Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $423.8 million in 2021, then surged by 37.68% to $583.4 million in 2022, then grew by 6.53% to $621.5 million in 2023, then soared by 35.24% to $840.6 million in 2024, then fell by 2.02% to $823.6 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $823.6 million for Q3 2025, versus $801.7 million for Q2 2025 and $846.5 million for Q1 2025.